Our findings are supported by results from murine models of gouty arthritis, ulcerative colitis, and cytomegalovirus infection, which suggest that targeting ASC can inhibit the activation of the NLRP3 and AIM2 inflammasome and alleviate inflammation 39. Here, NLRP3 is linked to ulcerative colitis.